Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study
This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.
Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.
Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.
The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.
Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.
The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.
The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Pernille Kølbæk, MD PhD
- 電話番号:004561397432
- メール:perpet@rm.dk
研究連絡先のバックアップ
- 名前:Ana Lisa Carmo, Psychiatrist
- 電話番号:0045 61155056
- メール:ANAMAR@rm.dk
研究場所
-
-
-
Aarhus N、デンマーク
- Aarhus University Hospital
-
コンタクト:
- Pernille Kølbæk, MD PhD
- 電話番号:004561397432
- メール:perpet@rm.dk
-
コンタクト:
- Ana Lisa Carmo, Psychiatrist
- 電話番号:0045 61155056
- メール:ANAMAR@rm.dk
-
主任研究者:
- Ana Lisa Carmo, Psychiatrist
-
Horsens、デンマーク
- Regional Psychiatry Horsens
-
コンタクト:
- Pernille Kølbæk, MD PhD
- 電話番号:004561397432
- メール:perpet@rm.dk
-
コンタクト:
- Thea Grønfeldt, Psychiatrist
- 電話番号:00457847 9258
- メール:theafaer@rm.dk
-
主任研究者:
- Pernille Kølbæk, MD PhD
-
Viborg、デンマーク
- Regional Psychiatry Central Jutland
-
コンタクト:
- Pernille Kølbæk, MD PhD
- 電話番号:004561397432
- メール:perpet@rm.dk
-
主任研究者:
- Ana Lisa Carmo, Psychiatrist
-
コンタクト:
- Ana Lisa Carmo, Psychiatrist
- 電話番号:004561155056
- メール:ANAMAR@rm.dk
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age 18-70 years
- ICD-10 criteria for PTSD (F43.1)
- A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
- Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
- Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.
Exclusion Criteria:
- Organic mental disorders (F0)
- Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
- Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
- Active suicidality
- Any ongoing involuntary/coercive measures
- Any contraindications listed on the TMS Safety Checklist
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks.
After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I).
Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR.
Participants with sufficient response continue EMDR treatment alone.
|
All enrolled participants begin standardized EMDR treatment.
Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR.
Participants who show sufficient improvement continue EMDR alone.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Drop-out
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The primary outcome will be drop-out rates
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Treatment completion rates
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Symptom trajectories
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
時間枠:Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
|
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Changes in mental well-being
時間枠:From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディチェア:Pernille Kølbæk、Aarhus University Hospital
- 主任研究者:Ana Lisa Carmo、Aarhus University Hospital
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2502681
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。